Perrigo launches methazolamide tablets

DUBLIN — Perrigo announced the launch of methazolamide tablets, the generic version of Neptazane tablets. The product is a component of the rights the company received in connection with its acquisition of a portfolio of ophthalmic products from Fera Pharmaceuticals and its affiliates last year.



The drug is used for the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma and preoperatively in acute angle-closure glaucoma, where lowering the intraocular pressure is desired before surgery, according to the company. Estimated annual sales of the drug total $12 million.



"This launch reflects our continuing investment in new products, is a great addition to the portfolio of ophthalmic products Perrigo is marketing today and is just another example of our commitment to driving additional value for our shareholders," Perrigo's Chairman, President and CEO Joseph C. Papa, said.